WST Q3 deep dive: Biologics and regulatory tailwinds fuel margin expansion, HVP mix shift continues

Healthcare products company West Pharmaceutical Services (NYSE:WST) announced better-than-expected revenue in Q3 2026, with sales up 8.7% year on year to $874.5 million. The company’s full-year revenue guidance of $3.42 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $2.66 per share was 21.1% above analysts’ consensus estimates.

Is now the time to buy WST? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

West Pharmaceutical Services delivered a Q3 performance that exceeded Wall Street’s expectations, with management attributing growth to robust demand for high-value product (HVP) components, especially in biologics and GLP-1 therapies. CEO Michel Lagarde highlighted expanded capacity and operational improvements, noting, “The team focused on execution and unlocking new efficiencies, for instance, by integrating more automation onto the production floor.” Additionally, progress in automation and strong customer relationships contributed to positive momentum across core segments, supporting the substantial year-on-year operating margin expansion.

Looking ahead, West Pharmaceutical Services’ updated outlook is anchored by continued investment in HVP finishing capacity, global regulatory shifts favoring premium containment solutions, and broad-based growth in biologics. Management emphasized that the company’s strategy will focus on deepening customer partnerships and leveraging continuous improvement initiatives. Lagarde stated, “We think [GLP-1] is a durable growth driver for us in the years to come,” while CFO Bob McMahon added that ongoing upgrades tied to evolving regulations are expected to provide a multi-year tailwind for the business.

Key insights from management’s remarks

Management pointed to strong execution in proprietary products, regulatory-driven upgrades, and international expansion as central to outperformance in the quarter.

• HVP components drive growth: The Proprietary Products segment, particularly HVP components, experienced strong double-digit organic growth, driven by both GLP-1 therapies and non-GLP-1 demand, as well as ongoing upgrades prompted by regulatory changes.
• Biologics market momentum: Management cited a record pipeline of biologic drugs in clinical development as a major factor supporting robust demand for West’s injectable solutions, with biologics now comprising a larger share of overall revenue mix.
• Regulatory tailwinds: The rollout of Europe’s Annex 1 and similar draft guidance from U.S. regulators is prompting pharmaceutical customers to upgrade to higher-value containment systems, adding over 200 upgrade projects this year and establishing a multi-year growth runway.
• Asia Pacific expansion: The Asia Pacific region grew 42% year over year, led by India and China, with management emphasizing the introduction of GLP-1 therapies and broader opportunities for innovative drug launches in emerging markets.
• Operational optimization: Automation initiatives and capacity investments across global manufacturing sites contributed to improved service levels and margin gains, with management stressing ongoing continuous improvement and digitization as key levers for future performance.

Drivers of future performance

West Pharmaceutical Services expects regulatory-driven product upgrades, capacity investments, and secular growth in biologics to support high-single digit revenue growth and sustained margin expansion.

• Continuous improvement initiatives: Management is prioritizing digitization, automation, and de-bottlenecking of existing facilities to unlock additional output and efficiency, which is expected to support both growth and profitability without exceeding historical capital expenditure ranges.
• Regulatory environment as a tailwind: The adoption of stricter contamination standards globally is driving customers to upgrade to HVP components, which management views as a multi-year, secular trend supporting elevated revenue growth and positive product mix shifts.
• Biologics and GLP-1 pipeline strength: With innovation in biologic drugs at an all-time high and expanding applications for GLP-1 therapies, management sees a durable opportunity for expansion in both current and new therapeutic categories, despite potential headwinds from generics or alternative delivery formats.

Catalysts in upcoming quarters

In upcoming quarters, the StockStory team will be closely monitoring (1) the pace of HVP component upgrades as regulatory requirements evolve, (2) execution on capacity expansions and automation projects, and (3) the sustainability of growth in biologics and GLP-1 therapies. Progress in emerging markets and the ability to drive further operational efficiencies will also be important indicators of future performance.

West Pharmaceutical Services currently trades at $408.61, up from $404.30 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

High quality stocks for all market conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.